• Tempest Therapeutics appointed Andrew Fang as head of business development.
• Fang will lead global partnering, cross-border licensing, corporate transactions, with focus on China outreach.
• Appointment supports partnering talks for Phase 3-ready amezalpat program, including potential China development opportunities.
• Fang was founding partner, principal at YQ Advisors, where he worked on cross-border licensing, M&A, biotech financing, public-company strategic initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140800PRIMZONEFULLFEED9689112) on April 14, 2026, and is solely responsible for the information contained therein.